SEATTLE, Sept. 17 VLST Corp, a Seattle-based biotechnologycompany focused on the development of therapeutics for autoimmune andinflammatory disorders, today announced the appointments of Consuelo M.Blosch, M.D. as Vice President of Clinical and Regulatory and Dan Allison,Ph.D, as Senior Director of Therapeutic Design.
Blosch joins VLST from the Benaroya Research Institute at Virginia Mason(BRI), where she served as administrative director of the BRI ClinicalResearch Program. There, she provided leadership oversight to investigatorsinvolved in more than 200 clinical trials. Prior to BRI, Blosch held directorlevel positions at Immunex Corporation and NPS Pharmaceuticals, Inc. AtImmunex, where she worked from 1992 to 1998, Blosch directed the solublereceptor program, participating in the study design and overseeing themonitoring for clinical trials including those for ENBREL. At NPS, shedirected a global research program for a recombinant human parathyroid hormonefor the treatment of osteoporosis. Blosch received an M.D. from theUniversity of Massachusetts Medical School.
Allison joins VLST from ICOS Corporation, where he worked from 1992 to2007, and most recently served as Senior Director, Production Development. AtICOS, Allison was responsible for engineering antibodies and other proteinsused in clinical studies and also directed the development of microbial andmammalian expression systems used to produce those proteins. Prior to ICOS,Allison worked at Genencor International. Allison received a Ph.D. from theGenetics Department at the University of Washington and carried out post-doctoral studies in yeast cell biology at the Biozentrum in Basel, Switzerlandand in the Biochemistry Department at the University of Washington.
"Consuelo's vast experience in the implementation, direction and design ofclinical trials will be truly invaluable to VLST as we begin to advance ournovel product candidates toward clinical development," said Martin Simonetti,President and Chief Executive Officer of VLST. "In addition, Dan bringssignificant protein engineering expertise that will guide the design of ourtherapeutic candidates. We are pleased to have such talented individuals joinour team and look forward to their contributions."
VLST Corporation is a privately held biotechnology company dedicated tothe streamlined discovery and development of novel therapeutics for thetreatment of inflammatory and autoimmune disorders. The VLST approach combinesnovel bioinformatics and cutting-edge proteomics to provide a rapid andrational approach to identifying new targets for the development of novelbiologic therapies. The process used to identify clinically relevant targetsalso provides a path to developing biologic molecules that can be used fortarget validation studies. Such an approach offers the opportunity to improvethe prioritization of product candidates and reduce costs by improving theclinical success rate. The VLST discovery platform has primary applicationsfor the treatment of rheumatoid arthritis, Crohn's disease, multiplesclerosis, lupus and diabetes. For more information, please visithttp://www.vlstcorp.com.
SOURCE VLST Corporation